Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12555211 | 0.94 | KMT2A (0.47) | KMT2AMEN1MDM2ALDH1A1KDM4E | |
| SCHEMBL16316701 | 0.94 | KMT2A (0.42) | LMNAKMT2AMEN1MDM2ALDH1A1 | |
| SCHEMBL12894102 | 0.93 | LMNA (0.45) | LMNAKMT2AMEN1MDM2ALDH1A1 | |
| SCHEMBL1745934 | 0.92 | KMT2A (0.45) | LMNAKMT2AMEN1MDM2ALDH1A1 | |
| SCHEMBL20143503 | 0.92 | KMT2A (0.42) | LMNAKMT2AMEN1MDM2CASP3 | |
| SCHEMBL31146900 | 0.92 | KMT2A (0.45) | LMNAKMT2AMEN1MDM2ALDH1A1 | |
| SCHEMBL3367289 | 0.92 | KMT2A (0.45) | LMNAKMT2AMEN1MDM2ALDH1A1 | |
| SCHEMBL29470540 | 0.92 | KMT2A (0.45) | LMNAKMT2AMEN1MDM2ALDH1A1 | |
| SCHEMBL14416300 | 0.92 | KMT2A (0.42) | LMNAKMT2AMEN1MDM2ALDH1A1 | |
| SCHEMBL29368397 | 0.92 | KMT2A (0.45) | LMNAKMT2AMEN1MDM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130244939-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244939-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130130979-A1 | PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8071541-B2 | Methods for preparing internally constrained peptides and peptidomimetics | AILERON THERAPEUTICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7887845-B2 | Particle of a solid dispersion composed of a water soluble polymer and etravirine or salt thereof; etravirine FDA Orange book listed patent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20100234563-A1 | Methods for Preparing Internally Constrained Peptides and Peptidomimetics | NEW YORK UNIVERSITY | 2010-09-16 | — | — | US | disclosed |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2010-07-08 | — | — | US | disclosed |
| US-7741280-B2 | Multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-22 | — | — | US | disclosed |
| US-7528104-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080090760-A2 | Compositions and Methods for Inhibiting Cellular Proliferation | HEMBROUGH TODD | 2008-04-17 | — | — | US | disclosed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20070197772-A1 | METHODS FOR PREPARING INTERNALLY CONSTRAINED PEPTIDES AND PEPTIDOMIMETICS | NEW YORK UNIVERSITY (US) | 2007-08-23 | — | — | US | disclosed |
| US-7202332-B2 | Methods for preparing internally constrained peptides and peptidomimetics | NEW YORK UNIVERSITY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202332-B2 | Methods for preparing internally constrained peptides and peptidomimetics | NEW YORK UNIVERSITY (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070027074-A1 | Novel peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234563-A1 | Methods for Preparing Internally Constrained Peptides and Peptidomimetics | VIP, IAPP, PTMA | LMNA 65/4885KMT2A 4780/4885MEN1 528/4885 |
| US-20130244939-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | LMNA 4428/4885KMT2A 4517/4885MEN1 3831/4885 |
| US-20130130979-A1 | PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | LMNA 4124/4885KMT2A 4254/4885MEN1 3427/4885 |
| US-20070027074-A1 | Novel peptides that bind to the erythropoietin receptor | EPOR, PROKR1, EDNRB | LMNA 4428/4885KMT2A 4517/4885MEN1 3831/4885 |
| US-20070197772-A1 | METHODS FOR PREPARING INTERNALLY CONSTRAINED PEPTIDES AND PEPTIDOMIMETICS | VIP, IAPP, PTMA | LMNA 65/4885KMT2A 4780/4885MEN1 528/4885 |
| US-20080090760-A2 | Compositions and Methods for Inhibiting Cellular Proliferation | MKI67, VEGFA, HDGF | LMNA 1836/4885KMT2A 4395/4885MEN1 1098/4885 |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | LMNA 2758/4885KMT2A 4564/4885MEN1 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.